Who Pays My Doctor?

Healthcare provider profile · identity verified

Benjamin Nathaniel Lockshin, MD

Allopathic & Osteopathic Physicians|Dermatology · SILVER SPRING, MD · NPI 1275523110

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Benjamin Nathaniel Lockshin, MD received $758,149.11 in general payments during 2025 across 741 reported records.

Regeneron Healthcare Solutions, Inc. accounted for 14.5% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 26 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Opzelura, Rinvoq.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rinvoq by this doctor in 2024.

Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPZELURA as an associated drug or biological on 59568 records involving 12571 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Opzelura by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$758,149.11

741 reported records · 24 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Regeneron Healthcare Solutions, Inc. Unresolved — no canonical attribution shown $109,833.0414.5%912025
ABBVIE INC. Unresolved — no canonical attribution shown $106,703.4114.1%842025
Arcutis Biotherapeutics, Inc. Unresolved — no canonical attribution shown $97,137.3212.8%842025
UCB, Inc. Unresolved — no canonical attribution shown $92,574.5512.2%1282025
GENZYME CORPORATION Unresolved — no canonical attribution shown $92,274.4812.2%392025
Lilly USA, LLC Unresolved — no canonical attribution shown $85,790.6511.3%682025
Incyte Corporation Unresolved — no canonical attribution shown $61,442.478.1%732025
Organon LLC Unresolved — no canonical attribution shown $43,607.095.8%502025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $31,767.734.2%212025
Galderma Laboratories, L.P. Unresolved — no canonical attribution shown $15,858.192.1%262025
SUN PHARMACEUTICAL INDUSTRIES INC. Unresolved — no canonical attribution shown $15,292.522.0%152025
Boehringer Ingelheim Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $3,815.730.5%32025
Kowa Pharmaceuticals America, Inc. Unresolved — no canonical attribution shown $750.000.1%12025
LEO Pharma Inc. Unresolved — no canonical attribution shown $307.140.0%102025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $285.770.0%152025
Janssen Biotech, Inc. Unresolved — no canonical attribution shown $198.560.0%112025
PFIZER INC. Unresolved — no canonical attribution shown $158.970.0%92025
Regeneron Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $126.530.0%12025
Ortho Dermatologics, a division of Bausch Health US, LLC Unresolved — no canonical attribution shown $91.530.0%42025
Amgen Inc. Unresolved — no canonical attribution shown $62.640.0%22025
STRATA Skin Sciences, Inc. Unresolved — no canonical attribution shown $29.980.0%32025
Botanix SB Inc Unresolved — no canonical attribution shown $13.990.0%12025
Medimetriks Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $13.650.0%12025
Janssen Pharmaceuticals, Inc Unresolved — no canonical attribution shown $13.170.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$507,034.75116
Consulting Fee$122,752.5037
Travel and Lodging$82,363.41267
Honoraria$33,600.0010
Food and Beverage$12,286.28309
Education$112.172

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
DUPIXENT
Normalized: dupixent		 Biological GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., Regeneron Pharmaceuticals, Inc. $202,164.29 128 2025
Source payment records
ZORYVE
Normalized: zoryve		 Drug Arcutis Biotherapeutics, Inc., Kowa Pharmaceuticals America, Inc. $97,887.32 85 2025
Source payment records
Bimzelx
Normalized: bimzelx		 Biological UCB, Inc. $92,515.79 127 2025
Source payment records
EBGLYSS
Normalized: ebglyss		 Drug Lilly USA, LLC $77,024.07 50 2025
Source payment records
RINVOQ
Normalized: rinvoq		 Biological ABBVIE INC. $69,326.17 50 2025
Source payment records
OPZELURA
Normalized: opzelura		 Drug Incyte Corporation $61,442.47 73 2025
Source payment records
VTAMA
Normalized: vtama		 Drug Organon LLC $43,484.13 46 2025
Source payment records
SKYRIZI
Normalized: skyrizi		 Biological ABBVIE INC. $37,377.24 34 2025
Source payment records
Sotyktu
Normalized: sotyktu		 Drug E.R. Squibb & Sons, L.L.C. $30,591.73 20 2025
Source payment records
NEMLUVIO
Normalized: nemluvio		 Drug Galderma Laboratories, L.P. $15,858.19 26 2025
Source payment records
Leqselvi
Normalized: leqselvi		 Biological SUN PHARMACEUTICAL INDUSTRIES INC. $15,257.54 13 2025
Source payment records
SPEVIGO
Normalized: spevigo		 Drug Boehringer Ingelheim Pharmaceuticals, Inc. $3,815.73 3 2025
Source payment records
ADBRY
Normalized: adbry		 Biological LEO Pharma Inc. $307.14 10 2025
Source payment records
COSENTYX
Normalized: cosentyx		 Drug Novartis Pharmaceuticals Corporation $252.41 14 2025
Source payment records
TREMFYA
Normalized: tremfya		 Drug Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc $211.73 12 2025
Source payment records
CIBINQO
Normalized: cibinqo		 Drug PFIZER INC. $158.97 9 2025
Source payment records
LITFULO
Normalized: litfulo		 Drug PFIZER INC. $158.97 9 2025
Source payment records
TALTZ
Normalized: taltz		 Drug Lilly USA, LLC $92.73 5 2025
Source payment records
Cabtreo
Normalized: cabtreo		 Drug Ortho Dermatologics, a division of Bausch Health US, LLC $91.53 4 2025
Source payment records
  • 2025-02-05 · Ortho Dermatologics, a division of Bausch Health US, LLC · $23.46 · Open Payments source
  • 2025-05-12 · Ortho Dermatologics, a division of Bausch Health US, LLC · $23.57 · Open Payments source
  • 2025-07-08 · Ortho Dermatologics, a division of Bausch Health US, LLC · $21.72 · Open Payments source
  • 2025-09-16 · Ortho Dermatologics, a division of Bausch Health US, LLC · $22.78 · Open Payments source
JUBLIA
Normalized: jublia		 Drug Ortho Dermatologics, a division of Bausch Health US, LLC $91.53 4 2025
Source payment records
  • 2025-02-05 · Ortho Dermatologics, a division of Bausch Health US, LLC · $23.46 · Open Payments source
  • 2025-05-12 · Ortho Dermatologics, a division of Bausch Health US, LLC · $23.57 · Open Payments source
  • 2025-07-08 · Ortho Dermatologics, a division of Bausch Health US, LLC · $21.72 · Open Payments source
  • 2025-09-16 · Ortho Dermatologics, a division of Bausch Health US, LLC · $22.78 · Open Payments source
SILIQ
Normalized: siliq		 Drug Ortho Dermatologics, a division of Bausch Health US, LLC $91.53 4 2025
Source payment records
  • 2025-02-05 · Ortho Dermatologics, a division of Bausch Health US, LLC · $23.46 · Open Payments source
  • 2025-05-12 · Ortho Dermatologics, a division of Bausch Health US, LLC · $23.57 · Open Payments source
  • 2025-07-08 · Ortho Dermatologics, a division of Bausch Health US, LLC · $21.72 · Open Payments source
  • 2025-09-16 · Ortho Dermatologics, a division of Bausch Health US, LLC · $22.78 · Open Payments source
OTEZLA
Normalized: otezla		 Drug Amgen Inc. $62.64 2 2025
Source payment records
LIBTAYO
Normalized: libtayo		 Biological Regeneron Healthcare Solutions, Inc. $43.74 2 2025
Source payment records
Winlevi
Normalized: winlevi		 Drug SUN PHARMACEUTICAL INDUSTRIES INC. $34.98 2 2025
Source payment records
XTRAC
Normalized: xtrac		 Device STRATA Skin Sciences, Inc. $29.98 3 2025
Source payment records
SOFDRA
Normalized: sofdra		 Drug Botanix SB Inc $13.99 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
OPZELURA
opzelura		 2025 Opzelura 2024 12
Beneficiary count suppressed		 exact normalized Medicare Part D
RINVOQ
rinvoq		 2025 Rinvoq 2024 24
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
ABBVIE INC.
Exact reporting entity; no affiliate inference		 2025 RINVOQ
open payments reported associated product		 CMS Open Payments — General Payments
279238 supporting records · 34343 recipient NPIs · example record 1201352600 		Rinvoq · 2024
Exact normalized brand match · 1 Part D row		 24 suppressed by CMS
Incyte Corporation
Exact reporting entity; no affiliate inference		 2025 OPZELURA
open payments reported associated product		 CMS Open Payments — General Payments
59568 supporting records · 12571 recipient NPIs · example record 1225959946 		Opzelura · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Clobetasol PropionateClobetasol Propionate13674
Triamcinolone AcetonideTriamcinolone Acetonide12185
Dupixent PenDupilumab9011
MinoxidilMinoxidil7229
TacrolimusTacrolimus7253
Taltz AutoinjectorIxekizumab53suppressed
FluorouracilFluorouracil4641
Doxycycline HyclateDoxycycline Hyclate34suppressed
Dupixent SyringeDupilumab33suppressed
MupirocinMupirocin3327
KetoconazoleKetoconazole3216
MetronidazoleMetronidazole26suppressed
RinvoqUpadacitinib24suppressed
HydrocortisoneHydrocortisone2313
Cosentyx Sensoready (2 Pens)Secukinumab22suppressed
SpironolactoneSpironolactone20suppressed
TretinoinTretinoin19suppressed
Clindamycin PhosphateClindamycin Phosphate1611
Econazole NitrateEconazole Nitrate16suppressed
FluocinonideFluocinonide16suppressed
IvermectinIvermectin16suppressed
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim1414
NystatinNystatin13suppressed
Bimzelx AutoinjectorBimekizumab-Bkzx12suppressed
OpzeluraRuxolitinib Phosphate12suppressed
ValacyclovirValacyclovir Hcl12suppressed
Skyrizi PenRisankizumab-Rzaa11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $758,149.11 · 741 records Regeneron Healthcare Solutions, Inc. ADBRY, Bimzelx, CIBINQO, COSENTYX, Cabtreo, DUPIXENT, EBGLYSS, JUBLIA, LIBTAYO, LITFULO, Leqselvi, NEMLUVIO, OPZELURA, OTEZLA, RINVOQ, SILIQ, SKYRIZI, SOFDRA, SPEVIGO, Sotyktu, TALTZ, TREMFYA, VTAMA, Winlevi, XTRAC, ZORYVE 2 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error